ArticleCureus2025
The Role of Neutrophil-Lymphocyte Ratio in Identifying the Severity of Obstructive Sleep Apnea: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive sleep apnea (OSA) is a prevalent disorder characterized by recurrent episodes of upper airway blockage during sleep, leading to intermittent hypoxia and disturbed sleep patterns. It is often associated with systemic inflammation as well as metabolic and cardiovascular disorders. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a promising predictor of systemic inflammation. This study aimed to evaluate the role of NLR in assessing the severity of OSA. PATIENTS AND
methodsThis retrospective cross-sectional study included 100 adult patients diagnosed with OSA through overnight polysomnography at a sleep center in Baghdad, Iraq, from April 6 to October 3, 2025. Patients with active infections, chronic inflammatory or autoimmune diseases, malignancy, or hematologic disorders were excluded. The severity of OSA was classified based on the apnea-hypopnea index (AHI). Statistical analysis was performed using SPSS software (IBM Corp., Armonk, NY), with t-tests and Fisher's exact tests applied and receiver operating characteristic (ROC) analysis used to determine the diagnostic efficiency of NLR.
resultsAmong the 100 patients, 42% had mild OSA, 25% moderate OSA, and 33% severe OSA. Body mass index (BMI) was significantly higher among patients with severe OSA (p = 0.025). ROC analysis revealed that NLR significantly predicted severe OSA (area under the curve (AUC)= 0.760, p < 0.001). An optimal cut-off point of NLR = 3.6 achieved 78.7% sensitivity, 74.6% specificity, 94.1% negative predictive value (NPV), and 87.7% positive predictive value (PPV).
conclusionThe NLR shows promise as an accessible and cost-effective biomarker for identifying severe OSA. Elevated NLR values reflect the systemic inflammatory processes associated with intermittent hypoxia and may aid clinicians in assessing OSA severity, particularly when polysomnography is not readily available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.